CD19 and systemic lupus erythematosus: Intramuscular injection of mRNab‐LNPs reduces CD19+ B and plasma cells in lupus and rheumatoid arthritis mice, significantly alleviating histopathological changes and tissue injuries of skins, kidneys, and joints.